News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Merck & Co.
NEWS
JOBS
IN THE PRESS
AWARDS
NEWS
Drug Development
Esperion Therapeutics, Inc. Climbs As CEO Lauds Merck & Co.'s Zetia Data
November 19, 2014
·
2 min read
BioMidwest
If Investors Like Merck & Co.'s Zetia Results, They Will Love Esperion Therapeutics, Inc.’s, Says Citi
November 17, 2014
·
1 min read
ISI: Merck & Co.’s Zetia News The Rising Tide To Lift All LDL Boats
November 17, 2014
·
2 min read
Business
Sun Pharmaceutical Industries Ltd Denies Calling Off JV With Merck & Co.
November 17, 2014
·
1 min read
Biotech Bay
Newly Identified Rare Mutation Mimicked By Merck & Co.'s Zetia Cuts Heart Risk
November 14, 2014
·
1 min read
Biotech Bay
A Day Of Reckoning Approaches For Merck & Co. And Its Critics
November 14, 2014
·
1 min read
JOBS
Currently, there are no jobs for this company on BioSpace
Browse all jobs
here
Oops!
There was an issue retrieving the jobs list. Please reload the page to view more jobs.
Title
Location
Company Name
Desc
View details
IN THE PRESS
Press Releases
European Commission Approves KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) as First PD-1 Inhibitor Plus Antibody-Drug Conjugate Regimen for Adults With Cisplatin-Ineligible Resectable Muscle-Invasive Bladder Cancer
June 24, 2026
·
19 min read
Press Releases
Merck Collaborates with Versant Ventures to Launch Saturnus Bio to Advance Treatments for Rare Genetic Cardiomyopathies
June 24, 2026
·
3 min read
Press Releases
Merck KGaA, Darmstadt, Germany, Collaborates with Versant Ventures to Launch Saturnus Bio to Advance Treatments for Rare Genetic Cardiomyopathies
June 24, 2026
·
4 min read
Press Releases
Merck’s Tulisokibart Met Primary and Key Secondary Endpoints in the Phase 3 ATLAS-UC Induction-only Study in Patients With Moderately to Severely Active Ulcerative Colitis (UC)
June 22, 2026
·
7 min read
Press Releases
U.S. FDA Approves an Additional Indication for CAPVAXIVE® (Pneumococcal 21-valent Conjugate Vaccine) in Children and Adolescents Aged 2 through 17 at Increased Risk for Pneumococcal Disease
June 18, 2026
·
11 min read
Press Releases
Study Reveals Dog Owners and Veterinarians See Challenges in Treating Allergic Skin Disease, Highlighting a Need for a Targeted Rapid Onset Treatment for Dogs of All Ages
June 17, 2026
·
11 min read
Press Releases
Nectin Therapeutics Reports Encouraging Phase 1 Results for NTX1088 in Combination with Keytruda® (pembrolizumab) at ASCO 2026
June 17, 2026
·
3 min read
Press Releases
Nivi, Inc. and MSD Collaborate to Expand HPV Disease Awareness and Cervical Cancer Prevention Through AI-Powered Platform
June 16, 2026
·
4 min read
Press Releases
Protillion Biosciences Announces Drug Discovery Collaboration with Merck
June 16, 2026
·
2 min read
Press Releases
FDA Approves KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Each With WELIREG® (belzutifan), for Adjuvant Treatment of Certain Patients With Clear Cell Renal Cell Carcinoma (ccRCC)
June 14, 2026
·
19 min read
